As Biotechnology companies, Spero Therapeutics Inc. (NASDAQ:SPRO) and Kamada Ltd. (NASDAQ:KMDA) are our subject to compare. And more specifically their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Spero Therapeutics Inc.||10.53M||17.66||36.09M||-2.63||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 has Spero Therapeutics Inc. and Kamada Ltd.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Spero Therapeutics Inc.||-342.74%||-48.2%||-43.8%|
Spero Therapeutics Inc. and Kamada Ltd. Recommendations and Ratings are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Spero Therapeutics Inc.||0||0||1||3.00|
Spero Therapeutics Inc. has a consensus price target of $28.5, and a 168.61% upside potential.
Institutional & Insider Ownership
Institutional investors owned 53.7% of Spero Therapeutics Inc. shares and 25.39% of Kamada Ltd. shares. Spero Therapeutics Inc.’s share owned by insiders are 23.71%. Insiders Competitively, owned 27.75% of Kamada Ltd. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Spero Therapeutics Inc.||4.93%||-2.45%||17.32%||39.09%||4.47%||93.82%|
For the past year Spero Therapeutics Inc.’s stock price has bigger growth than Kamada Ltd.
On 8 of the 11 factors Kamada Ltd. beats Spero Therapeutics Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The companyÂ’s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra, a hepatitis B immunoglobulin; Hepatect CP, a hepatitis B immunoglobulin; and Megalotect, a CMV immunoglobulin. The company also provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. In addition, it offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; Human Transferrin for diagnostic assays and cell cultures; and coagulation factors comprising Factor VIII and Factor IX. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, graft-versus-host diseases, and transplantations. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.